{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T23:59:49Z","timestamp":1785196789971,"version":"3.55.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004462","name":"European Bank for Reconstruction and Development","doi-asserted-by":"publisher","award":["UM1TR004360"],"award-info":[{"award-number":["UM1TR004360"]}],"id":[{"id":"10.13039\/100004462","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim Corp USA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.japh.2026.103106","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:59:06Z","timestamp":1774630746000},"page":"103106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A cross-sectional study of prescribing rates for SGLT2 inhibitors and GLP-1 receptor agonists among primary care clinics with and without embedded pharmacists"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7560-9521","authenticated-orcid":false,"given":"Dave L.","family":"Dixon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2708-7145","authenticated-orcid":false,"given":"Teresa M.","family":"Salgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7992-2574","authenticated-orcid":false,"given":"Amanda","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7248-4890","authenticated-orcid":false,"given":"Tyler D.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haroon","family":"Hyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Kirschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri T.","family":"Musselman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonya M.","family":"Buffington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9159-4876","authenticated-orcid":false,"given":"Roy T.","family":"Sabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.japh.2026.103106_bib1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2337\/dci23-0085","article-title":"Economic costs of diabetes in the U.S. in 2022","volume":"47","author":"Parker","year":"2024","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.japh.2026.103106_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"10","key":"10.1016\/j.japh.2026.103106_bib3","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1 Suppl 1","key":"10.1016\/j.japh.2026.103106_bib4","first-page":"S207","article-title":"10. Cardiovascular disease and risk management: standards of care in Diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.japh.2026.103106_bib5","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.mayocp.2024.08.026","article-title":"Prescribing patterns of SGLT2 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes at cardiology, endocrinology, and primary care visits","volume":"100","author":"Dixon","year":"2025","journal-title":"Mayo Clin Proc"},{"issue":"25","key":"10.1016\/j.japh.2026.103106_bib6","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1016\/j.jacc.2018.08.2202","article-title":"Prescriber patterns of SGLT2i after expansions of U.S. food and drug administration labeling","volume":"72","author":"Vaduganathan","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.japh.2026.103106_bib7","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2337\/dc19-1943","article-title":"Trends in clinical characteristics and prescribing preferences for SGLT2 inhibitors and GLP-1 receptor agonists, 2013-2018","volume":"43","author":"Dave","year":"2020","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.japh.2026.103106_bib8","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.jacc.2019.01.029","article-title":"Prescription of glucagon-like Peptide-1 receptor agonists by cardiologists","volume":"73","author":"Vaduganathan","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.japh.2026.103106_bib9","article-title":"National trends in use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists by cardiologists and other specialties, 2015 to 2020","volume":"11","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"19","key":"10.1016\/j.japh.2026.103106_bib10","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1016\/j.jacc.2015.03.550","article-title":"2015 ACC health policy statement on cardiovascular team-based care and the role of advanced practice providers","volume":"65","author":"Brush","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.japh.2026.103106_bib11","first-page":"536","article-title":"Implementing optimal team-based care to reduce clinician burnout","volume":"8","author":"Smith","year":"2018","journal-title":"NAM Perspect"},{"issue":"24","key":"10.1016\/j.japh.2026.103106_bib12","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.japh.2026.103106_bib13","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults","volume":"71","author":"Whelton","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.japh.2026.103106_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.pec.2023.108091","article-title":"A meta-analysis of the impact of pharmacist interventions on clinical outcomes in patients with type-2 diabetes","volume":"120","author":"Zhang","year":"2024","journal-title":"Patient Educ Couns"},{"issue":"9596","key":"10.1016\/j.japh.2026.103106_bib15","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet Lond Engl"},{"issue":"13","key":"10.1016\/j.japh.2026.103106_bib16","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.jacc.2019.08.014","article-title":"Therapeutic inertia in cardiovascular disease prevention: time to move the bar","volume":"74","author":"Dixon","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.japh.2026.103106_bib17","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-135-9-200111060-00012","article-title":"Clinical inertia","volume":"135","author":"Phillips","year":"2012","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.japh.2026.103106_bib18","article-title":"Self-identified prescriber tendencies in sodium-glucose cotransporter-2 inhibitor outpatient prescribing","volume":"64","author":"Thompson","year":"2024","journal-title":"J Am Pharm Assoc Japha"},{"issue":"1","key":"10.1016\/j.japh.2026.103106_bib19","first-page":"19","article-title":"Physician perceptions of the safety and efficacy of GLP-1 receptor agonists: underestimation of cardiovascular risk reduction and discrepancies with clinical evidence","volume":"12","author":"Krishnan","year":"2025","journal-title":"J Cardiovasc Dev Dis"},{"issue":"3","key":"10.1016\/j.japh.2026.103106_bib20","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2337\/cd23-0023","article-title":"Special report: potential strategies for addressing GLP-1 and dual GLP-1\/GIP receptor agonist shortages","volume":"41","author":"Whitley","year":"2023","journal-title":"Clin Diabetes Publ Am Diabetes Assoc"},{"issue":"5","key":"10.1016\/j.japh.2026.103106_bib21","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.13172","article-title":"GLP-1 receptor agonist discontinuation among patients with obesity and\/or type 2 diabetes","volume":"7","author":"Do","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.japh.2026.103106_bib22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.japh.2021.10.007","article-title":"Impact of a clinical pharmacist on provider prescribing patterns in a primary care clinic","volume":"62","author":"Wei","year":"2022","journal-title":"J Am Pharm Assoc Japha"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319126000919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319126000919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T23:31:55Z","timestamp":1785195115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319126000919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1544319126000919"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2026.103106","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A cross-sectional study of prescribing rates for SGLT2 inhibitors and GLP-1 receptor agonists among primary care clinics with and without embedded pharmacists","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2026.103106","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103106"}}